Group 1 - The core point of the article is that specific shareholders plan to reduce their holdings in Guangkang Biochemical (300804.SZ) within three months through centralized bidding and block trading [1] Group 2 - Shareholders Huatuo Zhiying No. 2 Investment Partnership and Huatuo Zhiyuan No. 3 Investment Enterprise plan to collectively reduce their holdings by no more than 1.3198 million shares, which is approximately 1.7835% of the company's total share capital [1] - Shareholder Ruihong Kaiyin No. 1 Equity Investment Fund Partnership plans to reduce its holdings by no more than 1.98 million shares, accounting for about 2.6757% of the company's total share capital [1]

证券代码：300804 证券简称：广康生化 公告编号：2026-004 股东深圳市华拓至远叁号投资企业（有限合伙）、共青城华拓至盈贰号投资合 伙企业（有限合伙）、共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 广东广康生化科技股份有限公司（以下简称"公司"或"发行人"）特定股东共 青城华拓至盈贰号投资合伙企业（有限合伙）（以下简称"华拓至盈贰号"）、深圳 市华拓至远叁号投资企业（有限合伙）（以下合称"华拓至远叁号"）以及共青城瑞 宏凯银壹号股权投资基金合伙企业（有限合伙）（以下简称"瑞宏凯银壹号"）计划 自本公告披露之日起三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公 司股份。其中，华拓至盈贰号和华拓至远叁号计划合计减持不超过 1,319,800 股，即 不超过公司总股本的 1.7835%；瑞宏凯银壹号计划减持不超过 1,980,000 股，即不超 过公司总股本的 2.6757%。 公司近日收到华拓至盈贰号、华拓至远叁号及瑞宏凯银壹号 ...

证券代码：300804 证券简称：广康生化 公告编号：2026-003 广东广康生化科技股份有限公司 （一）本次股份质押基本情况 | 深圳市深 | 2026 | 年 | 至办理解除 | 个人 | 是（首发前限 | 担增信融 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡丹群 | 是 | 100.00 | 3.87% | 1.35% | 否 | 2 | 月 | 10 | 质押登记手 | 资金 | 售股） | 资担保有 | 日 | 续之日止 | 需求 | | 限公司 | | | | | | | | | | | | | | | | （二）股东股份累计质押情况 截至本公告披露日，公司控股股东、实际控制人及其一致行动人所持股份质 押情况如下： | 蔡丹群 | 2,582.00 | 34.89% | 200.00 | 300.00 | 11.62% | 4.05% | 300.00 | 100% | 2,282.00 | 100 ...

广东广康生化科技股份有限公司 证券代码：300804 证券简称：广康生化 公告编号：2026-002 一、股东减持情况 （一）股东减持股份情况 关于特定股东减持股份计划期限届满暨实施情况的公告 股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广东广康生化科技股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份预披露公告》（公 告编号：2025-048），公司股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合 伙）（以下简称"瑞宏凯银壹号"）计划于减持计划公告之日起三个交易日后的三个 月内（即 2025 年 10 月 18 日-2026 年 1 月 17 日）以集中竞价交易或大宗交易方式减 持公司股份累计不超过 1,980,000 股，即不超过本公司总股本的 2.6757%。 截至 2026 年 1 月 17 日，上述减持计划期限已届满。公司已收到上述股东发来的 ...

Core Insights - The expiration of the compound patent for Pyraclostrobin in China has led to a surge in domestic interest, with companies increasing registration, production, and promotion efforts [1][6] - As of 2024, there are 62 registered Pyraclostrobin products in China, including 32 active ingredients and 30 formulations, primarily targeting wheat and peanut crops [1][6] - The global market for Pyraclostrobin has seen significant growth, with sales expected to rise from $973 million in 2015 to $2.014 billion by 2024, and projected to reach $2.172 billion by 2025 [5][11] Industry Overview - Pyraclostrobin, developed by Bayer in 2004, is a broad-spectrum fungicide known for its low toxicity and effectiveness against various plant diseases [2][3] - It is particularly effective against diseases affecting cereals and legumes, making it a key product in the global fungicide market, holding an 8% market share [3][5] Market Dynamics - The Chinese market for Pyraclostrobin is expanding rapidly due to the high incidence of wheat diseases, particularly Fusarium head blight, which can cause yield losses of 10% to 20% in epidemic years [7][11] - The area affected by Fusarium head blight in China is projected to reach 15 million acres in 2024, an increase of 6 million acres from 2023 [7][8] Competitive Landscape - Major companies in the Pyraclostrobin sector include Hailir, Anhui Jiuyi, Nantong Taihe, and Guangdong Guokang, among others, with many expanding production capacity [9][10] - Hailir reported a revenue of 3.391 billion yuan in the first nine months of 2025, a 5.5% increase year-on-year, indicating strong market performance [10] Future Trends - The demand for Pyraclostrobin is expected to continue rising due to increasing occurrences of wheat diseases and advancements in application methods [11] - The market is becoming increasingly competitive, with potential oversupply leading to price fluctuations, necessitating companies to optimize production and enhance brand presence [12] - The trend towards formulation mixtures is anticipated to grow, as combining Pyraclostrobin with other chemicals can delay resistance development and enhance efficacy [13]

Core Viewpoint - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Bureau due to violations related to the management and use of raised funds, specifically regarding the purchase of non-principal guaranteed financial products without adequate risk disclosure [1][2]. Group 1: Regulatory Actions - The Guangdong Securities Regulatory Bureau issued a warning letter to Guangkang Biochemical and its executives, Cai Danqun and Chen Haixia, for failing to fulfill their responsibilities under the Information Disclosure Management Measures [2]. - The company was found to have used raised funds to purchase 179 financial products, of which 158 were non-principal guaranteed, without sufficient disclosure of the associated risks in their reports [1][2]. Group 2: Financial Details - Guangkang Biochemical was listed on the Shenzhen Stock Exchange's ChiNext on June 27, 2023, issuing 18.5 million shares at a price of 42.45 yuan per share, which currently trades below its initial offering price [2]. - The total amount raised by the company was 785.325 million yuan, with a net amount of 697.3657 million yuan after deducting issuance costs, which exceeded the initially planned amount by 6.1779 million yuan [2].

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Guangkang Biochemical (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper use of raised funds for cash management, specifically concerning the purchase of non-principal guaranteed financial products [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. [2025] 179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company used raised funds to purchase 179 financial products [1] Group 2: Financial Product Purchases - Out of the 179 financial products purchased, 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases was as follows: 14 in 2023, 68 in 2024, and 76 in 2025 [1] Group 3: Disclosure Issues - The company failed to adequately disclose the risks associated with purchasing non-principal guaranteed financial products in its annual reports [1] - Despite not incurring any principal losses, the company's actions did not comply with regulatory requirements outlined in the "Regulatory Guidelines for Listed Companies on the Management and Use of Raised Funds" [1]

Core Viewpoint - Guangkang Biotech (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper management of raised funds, specifically concerning the purchase of non-principal guaranteed financial products without adequate disclosure of associated risks [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. 〔2025〕179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company engaged in cash management using raised funds [1] Group 2: Fund Management Practices - The company executed 179 transactions to purchase financial products, of which 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases includes 14 in 2023, 68 in 2024, and 76 in 2025 [1] - The company failed to adequately disclose the risks of potential principal loss in its annual reports regarding the use of raised funds [1] Group 3: Compliance Violations - The company's actions were found to be non-compliant with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" [1] - Violations included not fully disclosing the safety of principal when using raised funds for cash management [1]

广康生化公告，公司因在2023年7月至2025年8月期间，循环使用募集资金滚动购买179笔理财产品，其 中有158笔为非保本理财产品，且在相应年度《募集资金存放与使用专项报告》中未充分披露使用募集 资金进行现金管理的本金安全性问题，收到广东证监局出具的警示函。 ...